Stock 4174 OBI PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News OBI Pharma, Inc.

Equities

4174

TW0004174008

End-of-day quote Taipei Exchange
Other stock markets
 06:00:00 2024-05-21 pm EDT 		5-day change 1st Jan Change
59.8 TWD -0.50% Intraday chart for OBI Pharma, Inc. -1.32% -13.83%
May. 10 Obi Pharma, Inc. Announces the Termination of License Agreement with Odeon for the Rights of Obi-999 and Obi-833 in China, Hong Kong and Macau CI
Mar. 26 OBI Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Obi Pharma, Inc. Announces the Termination of License Agreement with Odeon for the Rights of Obi-999 and Obi-833 in China, Hong Kong and Macau
CI
OBI Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
OBI Pharma Announces Poster Presentations at the AACR 2024 Annual Meeting for OBI-992 and GlycOBI™ ADC platform
GL
OBI Pharma Announces Poster Presentations at the AACR 2024 Annual Meeting for OBI-992 and GlycOBI™ ADC platform
AQ
Obi Pharma, Inc. Announces the Termination of Obi-3424-001 Trial While Continuing the Collaboration Of obi-3424 with Partners
CI
OBI Pharma, Inc. Announces Adagloxad Simolenin (OBI-822) Receives Positive 1st Interim Analysis Recommendation, Recommending the Continues of the Phase III TNBC Trial
CI
Biosion's Partner OBI Pharma Announces FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992
AQ
OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992
GL
OBI Pharma, Inc. Announces OBI-992 TROP2 ADC Has Been Granted by US FDA to Proceed to Phase I/II Human Clinical Trial
CI
OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992
AQ
OBI Pharma, Inc. Announces Resignation of Yun Yen as Chairperson and Director, Effective December 29, 2023
CI
Obi Pharma, Inc. Files the Application of Phase I/II Human Clinical Trial for OBI-992 TROP2 ADC to US FDA
CI
OBI Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
OBI Pharma, Inc. Announces Head Office Address Change
CI
OBI Pharma, Inc. Announces Internal Audit Officer Changes
CI
OBI Pharma, Inc. Announces CFO Changes
CI
OBI Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
OBI Pharma, Inc. Announces Executive Changes
CI
OBI Pharma, Inc. Announces Appointment of Yun Yen as the Chairman
CI
OBI Pharma, Inc. Announces Appointment of Yun Yen as Natural-Person Director
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4174 Stock
  4. News OBI Pharma, Inc.